Sanofi and GSK announced today the initiation of a new phase 2 study of their adjuvanted recombinant protein COVID-19 vaccine candidate. The study will evaluate the candidate's safety, reactogenicity, and immunogenicity, and if successful, will support selection of the most appropriate antigen dosage for phase 3.
Two vaccine candidates against COVID-19
As the pandemic continues, Sanofi is pursuing vaccine development, while carrying on the daily business of making and delivering medicines for patients
How Sanofi COVID-19 vaccine candidates are designed
Sanofi is taking a two-pronged approach to vaccine development to help meet global public health needs during the coronavirus pandemic.
How is a protein-based vaccine designed to work?
How Clinical Trials Work for Our Adjuvanted Recombinant protein COVID-19 vaccine candidate
When Sanofi teams seek to make a new vaccine, they look to answer one simple question: Can the vaccine do what they expect it to do? In other words, they aim to demonstrate that our COVID-19 vaccine meet the specific medical objectives set for it when given to the people who need it most. This is our process for study of our adjuvanted recombinant protein vaccine candidate.
Frequently Asked Questions (FAQ)
The Impact of COVID-19 on the Prevention and Diagnosis of other Diseases
Vaccines: our best line of defense against infectious diseases like COVID-19
Critical Routine Vaccinations: Getting Back on Track
Preventing the Preventable: Influenza Vaccination in the Time of COVID-19
World Polio Day: Driving Polio Out of Sight, Never Out of Mind
Developing COVID-19 Vaccines: Behind the Scenes
Supporting People with Cancer during COVID-19
The Impact of COVID-19 on Cancer
